A Phase Ib/II, Open Label Study of Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation
Latest Information Update: 08 May 2024
At a glance
- Drugs Sabatolimab (Primary) ; Azacitidine; Azacitidine
- Indications Acute myeloid leukaemia; Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms STIMULUS-AML2
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 01 May 2024 Planned End Date changed from 1 Apr 2027 to 22 Aug 2024.
- 01 May 2024 Planned primary completion date changed from 7 Nov 2024 to 4 Jul 2024.
- 01 May 2024 Status changed from active, no longer recruiting to recruiting.